- Home
- CDNL vs CDNA Comparison
CDNL vs CDNA Comparison
Compare CDNL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDNL | CDNA |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 1.1B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | CDNL | CDNA |
|---|---|---|
| Price | $53.25 | $19.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $38.00 | $28.00 |
| AVG Volume (30 Days) | 420.1K | ★ 733.8K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $50.30 | $16.01 |
| Revenue Next Year | $8.41 | $11.31 |
| P/E Ratio | ★ $0.01 | $409.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $21.98 | $10.96 |
| 52 Week High | $63.18 | $23.24 |
Technical Indicators
Market Signals| Indicator | CDNL | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 47.72 |
| Support Level | $24.46 | $16.63 |
| Resistance Level | $54.55 | $21.20 |
| Average True Range (ATR) | 5.27 | 1.33 |
| MACD | -0.34 | -0.22 |
| Stochastic Oscillator | 46.12 | 38.34 |
Price Performance
Historical ComparisonAbout CDNL Cardinal Infrastructure Group Inc. Class A Common Stock
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. Its operations leverage a large highly skilled workforce and a fleet of specialized equipment to deliver wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.